GarcÃa-Molina, P.; Sola-Leyva, A.; Luque-Navarro, P.M.; Laso, A.; RÃos-Marco, P.; RÃos, A.; Lanari, D.; Torretta, A.; Parisini, E.; López-Cara, L.C.;
et al. Anticancer Activity of the Choline Kinase Inhibitor PL48 Is Due to Selective Disruption of Choline Metabolism and Transport Systems in Cancer Cell Lines. Pharmaceutics 2022, 14, 426.
https://doi.org/10.3390/pharmaceutics14020426
AMA Style
GarcÃa-Molina P, Sola-Leyva A, Luque-Navarro PM, Laso A, RÃos-Marco P, RÃos A, Lanari D, Torretta A, Parisini E, López-Cara LC,
et al. Anticancer Activity of the Choline Kinase Inhibitor PL48 Is Due to Selective Disruption of Choline Metabolism and Transport Systems in Cancer Cell Lines. Pharmaceutics. 2022; 14(2):426.
https://doi.org/10.3390/pharmaceutics14020426
Chicago/Turabian Style
GarcÃa-Molina, Pablo, Alberto Sola-Leyva, Pilar M. Luque-Navarro, Alejandro Laso, Pablo RÃos-Marco, Antonio RÃos, Daniela Lanari, Archimede Torretta, Emilio Parisini, Luisa C. López-Cara,
and et al. 2022. "Anticancer Activity of the Choline Kinase Inhibitor PL48 Is Due to Selective Disruption of Choline Metabolism and Transport Systems in Cancer Cell Lines" Pharmaceutics 14, no. 2: 426.
https://doi.org/10.3390/pharmaceutics14020426
APA Style
GarcÃa-Molina, P., Sola-Leyva, A., Luque-Navarro, P. M., Laso, A., RÃos-Marco, P., RÃos, A., Lanari, D., Torretta, A., Parisini, E., López-Cara, L. C., Marco, C., & Carrasco-Jiménez, M. P.
(2022). Anticancer Activity of the Choline Kinase Inhibitor PL48 Is Due to Selective Disruption of Choline Metabolism and Transport Systems in Cancer Cell Lines. Pharmaceutics, 14(2), 426.
https://doi.org/10.3390/pharmaceutics14020426
